SUN PHARMA ADV.RES.CO.LTD

Develops a clinical-stage pharmaceutical pipeline focused on oncology, immunology, and dermatology-autoimmune diseases, with two priority programs — SCD-153 (topical itaconate for alopecia areata with Johns Hopkins) and SBO-154 (a MUC1-targeting MMAE antibody-drug conjugate) — in Phase 1 trials running in the US, Australia and India. FY26 reported revenue of Rs 1,879.17 cr came almost entirely from a one-time Priority Review Voucher (PRV) granted by the US FDA upon approval of Sezaby, a treatment for neonatal seizures, and subsequently sold for USD 195 million in April 2026; underlying pharmaceutical R&D activities generated only Rs 3,915 lakhs in regular revenue. Earlier licensed products include Xelpros, Elepsia, Taclantis, PDP-716 and SDN-037, although the November 2019 China licence with CMS Bridging was terminated in June 2026 and the PDP-716 NDA received a Complete Response Letter in May 2026 over manufacturing-site inspection findings. The portfolio also includes preclinical work on targeted oncology and synthetic lethality, an out-licensed CML asset (Vodobatinib) now effectively in limbo, and SCO-155 advanced via a NewCo partnership template (Tiller Therapeutics). Headcount was cut from 400+ to ~250 in the cost optimisation programme, with management citing $10 million in annual fixed-cost savings, and approximately Rs 150 crore was raised upfront from a Rs 600 crore preferential warrant issue to the promoter group. Operating cost shape is dominated by employees (6.3% of revenue) and other opex (7.4%), with materials at just 1.3%, consistent with a clinical R&D business.